Afrezza Improving On The Cost Side, But The Revenue Side Still Needs Help | MNKD Message Board Posts


MannKind Corporation

  MNKD website

MNKD   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message    Post Message    Post a Reply return to message boardtop of board
Msg  17838 of 17860  at  8/9/2022 7:20:11 PM  by

tocentsworth

The following message was updated on 8/17/2022 12:26:39 PM.

Afrezza Improving On The Cost Side, But The Revenue Side Still Needs Help

Afrezza's gross profit is improving markedly, but it is not based on significantly increased Afrezza sales volume. Rather, its Cost of Goods Sold is coming down. According to the News Release, its manufacturing costs are coming down with an additional Danbury manufactured product (i.e. Tyvaso DPI), and a costly insulin supply agreement amendment fee in 2021 that did not repeat. I would think that the dollar's 2022 strength vs. the Euro also helped. JMHO.
 
 
 
 


     e-mail to a friend      printer-friendly     add to library      
|  
Recs: 0  
   Views: 0 []
Previous Message  Next Message    Post Message    Post a Reply return to message boardtop of board




Financial Market Data provided by
.
Loading...